Trial Outcomes & Findings for Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation (NCT NCT06080477)
NCT ID: NCT06080477
Last Updated: 2026-08-31
Results Overview
Feasibility will be evaluated by measuring the proportion of participants retained in the study (participants enrolled at baseline who are still enrolled in the trial through 12 months).
COMPLETED
NA
178 participants
12 months
2026-08-31
Participant Flow
Study recruitment began in December 2023. Recruitment occurred in Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi.
Sixty-seven participants were screened for eligibility. Among those, seven were ineligible, and sixty provided informed consent. All consenting participants were randomized. Each person living with psychosis could participate with up to two caregivers. Caregivers provided consent and participated in study activities, but no outcome or adverse event data were collected. Results data presented reflect the randomized persons living with psychosis for whom outcome data were collected and analyzed.
Participant milestones
| Measure |
Adapted ENHANCE Intervention
Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
|
Enhanced Usual Care
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Participants With Psychosis
STARTED
|
30
|
30
|
|
Participants With Psychosis
COMPLETED
|
29
|
29
|
|
Participants With Psychosis
NOT COMPLETED
|
1
|
1
|
|
Caregivers
STARTED
|
58
|
60
|
|
Caregivers
COMPLETED
|
58
|
60
|
|
Caregivers
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Data are reported separately for Participants With Psychosis and Caregivers.
Baseline characteristics by cohort
| Measure |
Adapted ENHANCE Intervention
n=88 Participants
Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
|
Enhanced Usual Care
n=90 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
Total
n=178 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
Participants With Psychosis
|
37.5 Years
STANDARD_DEVIATION 11.0 • n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
38.7 Years
STANDARD_DEVIATION 13.8 • n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
38.1 Years
STANDARD_DEVIATION 12.4 • n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Age, Continuous
Caregivers
|
43.4 Years
STANDARD_DEVIATION 14.4 • n=58 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
44.1 Years
STANDARD_DEVIATION 16.3 • n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
43.7 Years
STANDARD_DEVIATION 15.5 • n=118 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Sex: Female, Male
Participants With Psychosis · Female
|
6 Participants
n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
8 Participants
n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
14 Participants
n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Sex: Female, Male
Participants With Psychosis · Male
|
24 Participants
n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
22 Participants
n=30 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
46 Participants
n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Sex: Female, Male
Caregivers · Female
|
42 Participants
n=58 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
34 Participants
n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
76 Participants
n=118 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Sex: Female, Male
Caregivers · Male
|
16 Participants
n=58 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
26 Participants
n=60 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
42 Participants
n=118 Participants • Data are reported separately for Participants With Psychosis and Caregivers.
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: BaselinePopulation: The overall number of participants analyzed is equal to the total number of participants screened for eligibility. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
This measure is the ability to successfully enroll people with lived experience (PWLE) in the pilot intervention. Feasibility will be evaluated by measuring the number of participants approached in order to accrue the final sample.
Outcome measures
| Measure |
Total
n=67 Participants
Total of all reporting groups
|
Enhanced Usual Care
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Number of Participants Approached to Meet Enrollment (Recruitment Feasibility)
|
60 Participants
|
—
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Feasibility will be evaluated by measuring the proportion of participants retained in the study (participants enrolled at baseline who are still enrolled in the trial through 12 months).
Outcome measures
| Measure |
Total
n=30 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=30 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Proportion of Participants Retained in the Study (Retention Feasibility)
|
0.97 proportion of participants
|
0.97 proportion of participants
|
PRIMARY outcome
Timeframe: Conclusion of study, Month 12Population: The overall number of participants analyzed is equal to a subset of intervention participants who participated in a qualitative interview. This outcome does not apply to Enhanced Usual Care and no data were collected. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
A subset of intervention participants were asked if they were willing to participate in a qualitative interview. The 12 who agreed to participant were asked a series of qualitative questions including whether or not the intervention was helpful or unhelpful as a measure of satisfaction to inform intervention acceptability. The number indicating "helpful" as their response are reported.
Outcome measures
| Measure |
Total
n=12 Participants
Total of all reporting groups
|
Enhanced Usual Care
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Number of Participants Who Found the Intervention Helpful (Intervention Acceptability)
|
12 Participants
|
—
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: The overall number of participants analyzed is equal to the total number of intervention participants minus one participant in the intervention group who passed away. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
The total number of participants who completed all three intervention phases, out of the number of all intervention participants. This outcome does not apply to Enhanced Usual Care and no data were collected.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Number of Intervention Participants Who Completed All Intervention Phases (Intervention Attendance Fidelity)
|
27 Participants
|
—
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Level of functioning will be evaluated using the World Health Organization Disability Assessment Schedule (WHODAS 2.0 12-item version). The WHODAS 2.0 measures general disability related to multiple domains (i.e., understanding and communicating, getting around, self care, getting along with people, life activities, work/school, participation in society). Total scores on each item range from 1 (no disability) to 5 (extreme/cannot do), with higher scores indicating more impairment. Total scores on the scale range from 12 to 60, with higher scores indicating more impairment.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Overall Functioning
|
14.4 Score on a scale
Standard Deviation 3.6
|
15.7 Score on a scale
Standard Deviation 3.4
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Quality of life will be evaluated using the Short Form-8 (SF-8). The SF-8 is a shorter, 8-item questionnaire that covers the same eight domains as the full SF-36. The 8 items are scored using normed scoring that ranges from 0 to 100, with higher scores indicative of better quality of life.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Quality of Life Based on Short-Form 8 Measure
|
52.7 Score on a scale
Standard Deviation 5.7
|
50.8 Score on a scale
Standard Deviation 6.7
|
SECONDARY outcome
Timeframe: Baseline,12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Change in psychosis symptoms from baseline were evaluated using the Positive and Negative Symptoms Scale total scores (PANSS). Total scores range from 30 to 210 and include the total sum of all three sub-scales, with higher scores indicating worse outcomes. Scores reported are the change in symptoms relative to baseline.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Change in PANSS Total Score From Baseline
|
-25.2 Score on a scale
Standard Deviation 25.2
|
-18.4 Score on a scale
Standard Deviation 19.1
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Psychosis symptom response will be defined as the number of participants with a ≥20% reduction in symptoms from baseline as measured using the Positive and Negative Symptoms Scale (PANSS) total score. Total scores range from 30 to 210 and include a sum of all three sub-scales, with higher scores indicating worse outcomes.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Psychosis Symptom Response
|
20 Participants
|
15 Participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Psychosis symptom remission was evaluated using the Positive and Negative Symptoms Scale (PANSS). Each PANSS item was scored on a scale from 1 to 7 with 1 = "absent" and and 7 = "extreme" with higher values indicating worse symptoms. Remission was defined as the number of participants who responded as having absent or minimal symptoms on items G5, G9, N1, N4, N6, and P1-3 in the PANSS.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Psychosis Symptom Remission
|
26 Participants
|
23 Participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Clinical improvement will be evaluated using the Clinical Global Impression-Improvement score (CGI-I). Clinical improvement will be measured as the number of participants with a score of 1 ("very much improved") or 2 ("much improved"). The CGI-I is a 1-7 scale, designed to evaluate improvement through a comparison with the initial assessment of the patient at baseline. Possible ratings range from "very much improved" (score of 1) to "very much worse" (score of 7).
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Clinical Improvement
|
27 Participants
|
27 Participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The analysis population for each group excludes one participant who died: one from the adapted ENHANCE intervention group and one from the usual care group. Data reflect persons living with psychosis participants only. Outcome measure data were not collected for caregivers and are not reported.
Internalized stigma will be evaluated using the Internalized Stigma of Mental Illness Inventory (ISMI). A total score is calculated by taking a sum of the responses on the items (range=10 to 40). Higher total scores indicate greater internalized stigma.
Outcome measures
| Measure |
Total
n=29 Participants
Total of all reporting groups
|
Enhanced Usual Care
n=29 Participants
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Internalized Stigma
|
23.93 Score on a scale
Standard Deviation 2.5
|
23.72 Score on a scale
Standard Deviation 2.4
|
Adverse Events
Adapted ENHANCE Intervention
Enhanced Usual Care
Serious adverse events
| Measure |
Adapted ENHANCE Intervention
n=30 participants at risk
Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
|
Enhanced Usual Care
n=30 participants at risk
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Psychiatric disorders
Hospitalization due to relapse of psychotic symptoms.
|
3.3%
1/30 • Adverse event data were collected from enrollment until the end of follow-up, up to approximately 12 months post-consent. All-Cause Mortality, Serious, and Other (Not including serious) adverse events were not assessed, monitored, or collected for the caregivers.
Deaths were assessed systematically for any participant lost to contact through consultation of clinical records and community tracing. Hospitalizations and suicidal ideation were queried systematically at each research assessment. Suicidal ideation was defined as any thoughts of self-harm or being better off dead in the past two weeks, as assessed by question 9 of the Patient Health Questionnaire-9. Data reflect persons living with psychosis participants only.
|
3.3%
1/30 • Adverse event data were collected from enrollment until the end of follow-up, up to approximately 12 months post-consent. All-Cause Mortality, Serious, and Other (Not including serious) adverse events were not assessed, monitored, or collected for the caregivers.
Deaths were assessed systematically for any participant lost to contact through consultation of clinical records and community tracing. Hospitalizations and suicidal ideation were queried systematically at each research assessment. Suicidal ideation was defined as any thoughts of self-harm or being better off dead in the past two weeks, as assessed by question 9 of the Patient Health Questionnaire-9. Data reflect persons living with psychosis participants only.
|
Other adverse events
| Measure |
Adapted ENHANCE Intervention
n=30 participants at risk
Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care
|
Enhanced Usual Care
n=30 participants at risk
Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team
|
|---|---|---|
|
Psychiatric disorders
Suicidal ideation
|
16.7%
5/30 • Adverse event data were collected from enrollment until the end of follow-up, up to approximately 12 months post-consent. All-Cause Mortality, Serious, and Other (Not including serious) adverse events were not assessed, monitored, or collected for the caregivers.
Deaths were assessed systematically for any participant lost to contact through consultation of clinical records and community tracing. Hospitalizations and suicidal ideation were queried systematically at each research assessment. Suicidal ideation was defined as any thoughts of self-harm or being better off dead in the past two weeks, as assessed by question 9 of the Patient Health Questionnaire-9. Data reflect persons living with psychosis participants only.
|
16.7%
5/30 • Adverse event data were collected from enrollment until the end of follow-up, up to approximately 12 months post-consent. All-Cause Mortality, Serious, and Other (Not including serious) adverse events were not assessed, monitored, or collected for the caregivers.
Deaths were assessed systematically for any participant lost to contact through consultation of clinical records and community tracing. Hospitalizations and suicidal ideation were queried systematically at each research assessment. Suicidal ideation was defined as any thoughts of self-harm or being better off dead in the past two weeks, as assessed by question 9 of the Patient Health Questionnaire-9. Data reflect persons living with psychosis participants only.
|
Additional Information
Brian Pence, PhD, MPH
University of North Carolina at Chapel Hill
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place